Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets
Authors:
- 20 February 2025
- journal article
- review article
- Published by Springer Nature in Hepatology International
- Vol. 19 (2) , 325-336
Abstract
Hepatocellular carcinoma (HCC) is one of the common malignant cancers worldwide. Although immunotherapy has improved the treatment outcome in HCC, a significant percentage of patients with advanced HCC still cannot benefit from immunotherapy. Therefore, developing new targets or combination therapeutic strategies to improve the efficacy of immunotherapy is urgently needed. A deeper understanding of the mechanisms underlying immune regulation may help in this regard. The tumor microenvironment (TME) consists of a diverse set of components modulating the efficacy of immunotherapy. Cancer-associated fibroblasts (CAFs) are critical components of the TME and can regulate both tumor and immune cells through secreted cytokines and exosomes that impact various signaling pathways in target cells. CAF-derived cytokines can also participate in extracellular matrix (ECM) remodeling, thereby impacting cancer progression and tumor responsiveness to immunotherapy among other effects. A thorough understanding of the phenotypic and functional profile dynamism of CAFs may lead the way for new treatment strategies and/or better treatment outcomes in HCC patients. In this review, we outline the biomarkers and functional heterogeneity of CAFs in HCC and elaborate on molecular mechanisms of CAFs, including anti-programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) immunotherapy. We also examine current clinical implications of CAFs-related targets as potential therapeutic candidates in HCC.Keywords
This publication has 114 references indexed in Scilit:
- Cancer‐associated fibroblasts‐secreted exosomal miR‐92a‐3p promotes tumor growth and stemness in hepatocellular carcinoma through activation of Wnt/β‐catenin signaling pathway by suppressing AXIN1Journal of Cellular Physiology, 2024
- Matricellular proteins: Potential biomarkers in head and neck cancerJournal of Cell Communication and Signaling, 2024
- Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunityCell Biology International, 2024
- The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlasClinical and Translational Medicine, 2023
- Cancer‐associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD‐1 inhibitors and antiangiogenic agents in hepatocellular carcinomaCancer, 2023
- Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinibCancer Communications, 2023
- Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinomaHepatology, 2022
- Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma ProgressionHepatology, 2021
- Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analysesInternational Journal of Cancer, 2021
- LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2Journal of Cellular Physiology, 2017